Clinical Trials
1,954 trialsNivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
ADAPT NXT
argenx
SACHI
Hutchmed
FORTITUDE-101
Amgen
MK-4280A-007
Merck Sharp & Dohme LLC
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
MEN-301
NX Development Corp
Viale-a
AbbVie
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
BELINDA
Novartis
LEAP-012
Merck Sharp & Dohme LLC
SERENE
Sumitomo Pharma Switzerland GmbH
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
POLARIX
Hoffmann-La Roche
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Merck Sharp & Dohme LLC
KEYLYNK-001
Merck Sharp & Dohme LLC
ZEAL-1L
GlaxoSmithKline
KEYNOTE-991
Merck Sharp & Dohme LLC
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Harbour BioMed (Guangzhou) Co. Ltd.
CodeBreak300
Amgen
KEYNOTE-937
Merck Sharp & Dohme LLC
COMBI-AD
Novartis
FLAURA
AstraZeneca
INFINITE
Ferring Ventures Limited
NAPOLI 3
Ipsen
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
ENSPIRIT
Achieve Life Sciences
KEYNOTE-966
Merck Sharp & Dohme LLC
ENGOT-EN5
Karyopharm Therapeutics Inc
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
SKYSCRAPER-08
Hoffmann-La Roche
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sandoz
VIALE-M
AbbVie
DEB
Chipscreen Biosciences, Ltd.
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
V503-024
Merck Sharp & Dohme LLC
SKYSCRAPER-02
Hoffmann-La Roche
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
TirbAKare
Almirall, S.A.
KEYNOTE-966
Merck Sharp & Dohme LLC
TRANSFORM-1
AbbVie
MK-3475-775
Eisai Inc.
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.